

Dermira, Inc.
Form 10-Q
May 10, 2016
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36668

DERMIRA, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

27-3267680
(I.R.S. Employer
Identification Number)

275 Middlefield Road, Suite 150

Menlo Park, CA 94025

(Address of principal executive offices) (Zip Code)

(650) 421-7200

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer
(do not check if a smaller reporting company)

Smaller reporting company

Edgar Filing: Dermira, Inc. - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

As of April 29, 2016, the registrant had 30,018,641 shares of common stock outstanding.

Table of Contents

Dermira, Inc.

Quarterly Report on Form 10-Q

Index

| | Page No. |
|-------------------|---|
| <u>PART I</u> | <u>FINANCIAL INFORMATION</u> 3 |
| <u>ITEM 1:</u> | <u>Financial Statements (Unaudited)</u> 3 |
| | <u>Condensed Consolidated Balance Sheets</u> 3 |
| | <u>Condensed Consolidated Statements of Operations</u> 4 |
| | <u>Condensed Consolidated Statements of Comprehensive Loss</u> 5 |
| | <u>Condensed Consolidated Statements of Cash Flows</u> 6 |
| | <u>Notes to Condensed Consolidated Financial Statements</u> 7 |
| <u>ITEM 2:</u> | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 16 |
| <u>ITEM 3:</u> | <u>Quantitative and Qualitative Disclosures about Market Risk</u> 20 |
| <u>ITEM 4:</u> | <u>Controls and Procedures</u> 21 |
| <u>PART II</u> | <u>OTHER INFORMATION</u> 22 |
| <u>ITEM 1:</u> | <u>Legal Proceedings</u> 22 |
| <u>ITEM 1A:</u> | <u>Risk Factors</u> 22 |
| <u>ITEM 2:</u> | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> 61 |
| <u>ITEM 3:</u> | <u>Defaults Upon Senior Securities</u> 61 |
| <u>ITEM 4:</u> | <u>Mine Safety Disclosures</u> 61 |
| <u>ITEM 5:</u> | <u>Other Information</u> 61 |
| <u>ITEM 6:</u> | <u>Exhibits</u> 62 |
| <u>Signatures</u> | 63 |

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. Financial Statements****DERMIRA, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands)

| | March 31, 2016 (unaudited) | December 31, 2015 |
|---|----------------------------------|----------------------|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 92,371 | \$ 107,242 |
| Short-term investments | 96,932 | 107,451 |
| Prepaid expenses and other current assets | 3,893 | 2,540 |
| Total current assets | 193,196 | 217,233 |
| Property and equipment, net | 460 | 386 |
| Long-term investments | | 1,019 |
| Intangible assets | 1,126 | 1,126 |
| Goodwill | 771 | 771 |
| Other assets | 1,249 | 1,397 |
| Total assets | \$ 196,802 | \$ 221,932 |
| Liabilities and stockholders' equity | | |
| Current liabilities: | | |
| Accounts payable | \$ 12,540 | \$ 9,230 |
| Accrued liabilities | 14,101 | 16,666 |
| Total current liabilities | 26,641 | 25,896 |
| Long-term liabilities: | | |
| Deferred revenue | 10,000 | 10,000 |
| Deferred tax liability | 194 | 194 |
| Other long-term liabilities | 101 | 367 |
| Total liabilities | 36,936 | 36,457 |
| Commitments and contingencies (Note 6) | | |
| Stockholders' equity: | | |
| Preferred stock | | |
| Common stock | 30 | 30 |
| Additional paid-in capital | 349,272 | 346,590 |
| Accumulated other comprehensive gain (loss) | 48 | (97) |
| Accumulated deficit | (189,484) | (161,048) |
| Total stockholders' equity | 159,866 | 185,475 |
| Total liabilities and stockholders' equity | \$ 196,802 | \$ 221,932 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents**DERMIRA, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(in thousands, except share and per share amounts)****(unaudited)**

| | Three Months Ended March 31, | |
|--|---|-------------|
| | 2016 | 2015 |
| Operating expenses: | | |
| Research and development | \$ 22,854 | \$ 10,088 |
| General and administrative | 5,901 | 4,146 |
| Total operating expenses | 28,755 | 14,234 |
| Loss from operations | (28,755) | (14,234) |
| Interest and other income, net | 319 | 237 |
| Interest expense | | (38) |
| Net loss | \$ (28,436) | \$ (14,035) |
| Net loss per share, basic and diluted | \$ (0.95) | \$ (0.57) |
| Weighted-average common shares used to compute net loss per share, basic and diluted | 29,980,283 | 24,655,011 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

DERMIRA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

(unaudited)

| | Three Months Ended | |
|--|---------------------------|-------------|
| | March 31, | |
| | 2016 | 2015 |
| Net loss | \$ (28,436) | \$ (14,035) |
| Other comprehensive loss: | | |
| Unrealized gain on available-for-sale securities | 145 | 179 |
| Total comprehensive loss | \$ (28,291) | \$ (13,856) |

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

DERMIRA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)